Mark White is on the board of Annovis Bio, Inc.
He previously was Chief Executive Officer at Neurokine Therapeutics LLC, Senior Director & Group Leader-Pain Therapeutics at Pfizer Inc. and Senior Director-Marketing & Business Development at Bracco Diagnostics, Inc.
Mark White received an undergraduate degree and a graduate degree from the University of Missouri and an MBA from The University of Chicago Booth School of Business.
|10/12/2021||5,000||Acquisition at $27.4 per share.||137,000|
|01/31/2020||3,252||Derivative/Non-derivative trans. at $4.8 per share.||15,609|
|01/31/2020||34,643||Derivative/Non-derivative trans. at $0 per share.||0|
|01/31/2020||11,548||Derivative/Non-derivative trans. at $0 per share.||0|
|01/31/2020||1,734||Acquisition at $6 per share.||10,404|